Title KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Principal Investigator Maureen Ross, MD
Study Number 191211
Summary To measure the impact of donor selection for KIR genotype in allogeneic HCT for AML on cumulative incidence of relapse. This study will evaluate the incidence of relapse-free survival and overall survival, as well as endpoints not expected to be influenced by donor KIR selection including engraftment, GVHD and TRM. This study will determine the percentage of searches utilizing KIR genotyping to choose the best available KIR donor.
- Patient with acute myeloid leukemia (AML) undergoing screening for potential URD HCT.
- Potential URD undergoing screening to provide a HCT graft to a patient with acute myeloid leukemia (AML)
- Recipients with AML who are candidates for unrelated hematopoietic cell transplantation.
- Provide written consent.